[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338685-105":59,"doc-detail-338685-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","rbm15-facilitates-osimertinib-resistance-of-lung-adenocarcinoma-through-m6a-dependent-epigenetic-silencing-of-spock1","RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1","","RBM15 is identified as a key regulator in lung adenocarcinoma progression by linking N6-methyladenosine (m6A) dynamics to epigenetic silencing. The study shows RBM15 overexpression in lung adenocarcinoma associates with poor prognosis and promotes proliferation and migration. In EGFR-mutant tumors, RBM15 supports worse outcomes and drives osimertinib resistance by increasing m6A modification of SPOCK1 mRNA, triggering epithelial–mesenchymal transition (EMT) via a bypass activation pathway. Findings are validated in osimertinib-resistant H1975 cells and patient-derived organoids and further detected in drug-tolerant persister cells, suggesting early RBM15 targeting may extend TKI benefit.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rbm15-facilitates-osimertinib-resistance-of-lung-adenocarcinoma-through-m6a-dependent-epigenetic-silencing-of-spock1/338685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rbm15-facilitates-osimertinib-resistance-of-lung-adenocarcinoma-through-m6a-dependent-epigenetic-silencing-of-spock1/338685.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does RBM15 play in lung adenocarcinoma?","Question",{"text":113,"@type":114},"RBM15 is significantly overexpressed in lung adenocarcinoma and functions as an independent prognostic factor for poor outcomes, promoting tumor cell proliferation and migration.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does RBM15 influence osimertinib resistance?",{"text":118,"@type":114},"RBM15 enhances m6A modification of SPOCK1 mRNA, leading to epigenetic silencing that promotes EMT-mediated osimertinib resistance through a bypass activation pathway.",{"name":120,"@type":111,"acceptedAnswer":121},"How were the findings validated?",{"text":122,"@type":114},"The mechanism was validated in osimertinib-resistant H1975 cells and in organoids derived from patients with osimertinib-resistant lung adenocarcinoma.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338685,1790064223,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nRBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1  \nHongxiang Li1,2,10, Yin Li 3,10, Xiaoxiao Zheng4, Fangqian Chen5, Shufen Zhang4, Shuguang Xu6, Yinyu Mu1, Wei Shen7, Jingtao Tong6, Hang Chen1, Zeyang Hu 1,2, Jiaheng Zhang1,2, Keyue Qiu 1,2, Wei Chen 8,9 ✉, Xinghua Cheng 3 ✉ and Guodong Xu 1,2 ✉  \n© The Author(s) 2024  \n\n| | Lung cancer is the leading cause of cancer-related mortality globally. N6-methyladenosine (m6A) is the most abundant modiﬁcation in mammalian mRNA and is involved in the biological regulation of tumors, including lung cancer. However, the role of m6A-related proteins, such as RNA-binding motif protein 15 (RBM15), in lung cancer progression remains largely unknown. Our study indicated that RBM15 is signiﬁcantly overexpressed in lung adenocarcinoma, serving as an independent prognostic factor for poor outcomes and facilitating tumor cell proliferation and migration. RBM15 was markedly elevated in patients with EGFR mutations, correlating with a poorer prognosis, while it had negligible prognostic value in EGFR wild-type patients. As EGFR-tyrosine kinase inhibitors (TKIs) are the standard treatment for patients with EGFR mutations, we subsequently determined that RBM15 drives osimertinib resistance via a novel mechanism: enhancing m6A modiﬁcation of cwcv-and kazal-like domains proteoglycan 1 (SPOCK1) mRNA, promoting epithelial–mesenchymal transition-mediated osimertinib resistance through a bypass activation pathway. These ﬁndings were validated in osimertinib-resistant H1975 cells and organoids from patients with osimertinib-resistant lung adenocarcinoma. Furthermore, the RBM15–SPOCK1 axis was activated in drug-tolerant persister cells, indicating that early targeting of RBM15 during EGFR-TKI treatment could dramatically extend the patient response and beneﬁt from TKI therapy. Our results emphasize the critical role of RBM15 in reversing EGFR-TKI resistance and propose it as a promising therapeutic target for | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | prolonging TKI treatment beneﬁts in patients with lung adenocarcinoma. |  |\n|  |  |  |\n|  |  |  |\n|  | Oncogene (2025) 44:307–321; [https://doi.org/10.1038/s41388-024-03220-z](https://doi.org/10.1038/s41388-024-03220-z) |  |\n|  |  |  |\n\nHIGHLIGHTS  \n● RBM15 regulates the sensitivity of EGFR-mutant lung adenocarcinoma to osimertinib.  \n● RBM15 binds to SPOCK1 mRNA and inhibits its expression through an m6A-mediated mechanism.  \n● Knockdown of RBM15 enhances the sensitivity of resistant cells and resistant organoids to osimertinib by upregulating SPOCK1 expression.  \n● The RBM15–SPOCK1 axis promotes epithelial–mesenchymal transition-mediated osimertinib resistance through a bypass activation pathway.  \n● The RBM15–SPOCK1–EMT axis is activated early during osimertinib treatment, rather than during the advanced stage of tumor resistance.  \nINTRODUCTION  \nLung cancer remains a deadly cancer globally, with a 5-year survival rate of 10–20% in most regions, and its incidence continues to rise [1] . Non-small cell lung cancer (NSCLC) accounts for 85% of all cases, with lung adenocarcinoma (LUAD) comprising 53.3% of NSCLC cases [2] . Despite diagnosis and treatment pathway advancements, 85% of patients are diagnosed at an advanced stage [3] . Consequently, there is a critical need to explore the lung cancer onset and progression mechanisms.  \nN6-methyladenosine (m6A) is the most abundant modiﬁcation in mammalian mRNA [4] and is dynamically regulated by “writers”,“erasers”, and “readers” (collectively known as WERs) [5]. m6A is involved in the biological processes of diseases such as osteosarcoma  \n1Department of Thoracic Surgery, The Afﬁliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China. 2He","cbCaijfClyhqDaYT","https://ap.wps.com/l/cbCaijfClyhqDaYT","pdf",10725024,15,"English","# Highlights\n# Introduction","[{\"question\":\"What role does RBM15 play in lung adenocarcinoma?\",\"answer\":\"RBM15 is significantly overexpressed in lung adenocarcinoma and functions as an independent prognostic factor for poor outcomes, promoting tumor cell proliferation and migration.\"},{\"question\":\"How does RBM15 influence osimertinib resistance?\",\"answer\":\"RBM15 enhances m6A modification of SPOCK1 mRNA, leading to epigenetic silencing that promotes EMT-mediated osimertinib resistance through a bypass activation pathway.\"},{\"question\":\"How were the findings validated?\",\"answer\":\"The mechanism was validated in osimertinib-resistant H1975 cells and in organoids derived from patients with osimertinib-resistant lung adenocarcinoma.\"}]","RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1 | PDF",1790025065,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e20b99763433f461d29083bcfb06933c.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c55a23e76e126d51776bf2c1c7964b80.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/299c020f046cf363d6657b84774a978c.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84e084f06bbca7068c0f99bb97a061de.webp",980,1301]